News tagged with carboplatin
Clinical trials helped one woman's fight against cancer
(HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from ...
Cancer
Apr 18, 2013 |
not rated yet |
0
Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...
Cancer
Apr 15, 2013 |
not rated yet |
0
Paragazole excels in preclinical models of triple-negative breast cancer
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Cancer
Apr 08, 2013 |
5 / 5 (2) |
0
Understanding of the mechanisms of drug resistance to dual-agent chemotherapy in ovarian cancer
More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main ...
Cancer
Nov 29, 2012 |
not rated yet |
0
Optimal dose suggested for dasatinib in ovarian cancer
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...
Cancer
Nov 19, 2012 |
5 / 5 (1) |
0
Abraxane approved to treat advanced lung cancer
(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung ...
Cancer
Oct 14, 2012 |
not rated yet |
0
Genetically-engineered preclinical models predict pharmacodynamic response
New cancer drugs must be thoroughly tested in preclinical models, often in mice, before they can be offered to cancer patients for the first time in phase I clinical trials. Key components of this process include pharmacokinetic ...
Cancer
Sep 19, 2012 |
not rated yet |
0
|
Gene helps predict which ovarian cancer sufferers will benefit most from chemotherapy
(Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy ...
Cancer
Sep 19, 2012 |
not rated yet |
0
Tissue platinum concentrations linked to response in NSCLC
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according ...
Cancer
Aug 14, 2012 |
not rated yet |
0
Pre-op chemoradiotherapy ups survival in esophageal cancer
(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with ...
Cancer
May 31, 2012 |
not rated yet |
0
Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients ...
Cancer
Apr 17, 2012 |
not rated yet |
0
Harmless human virus may be able to boost the effects of chemotherapy
A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.
Cancer
Apr 03, 2012 |
5 / 5 (1) |
0
Drug combination may provide option to patients with NSCLC ineligible for bevacizumab
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual ...
Cancer
Apr 03, 2012 |
not rated yet |
0
Ototoxicity rates in children receiving carboplatin studied
(HealthDay) -- Retinoblastoma patients who are younger than 6 months of age at the start of carboplatin treatment experience a higher incidence of ototoxicity, according to a study published online Feb. 27 ...
Cancer
Feb 29, 2012 |
not rated yet |
0
Survival increased in early stage breast cancer after treatment with herceptin and chemo
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very ...
Cancer
Oct 05, 2011 |
not rated yet |
0
|
Carboplatin
Carboplatin, or cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) (trade names Paraplatin and Paraplatin-AQ) is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.
For more information about Carboplatin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
